CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia

T-cell Acute Lymphoblastic Leukemia Clinical Trial

Official title:

A Phase I Study of CD5 CAR-T for Refractory/Relapsed CD5+ T-ALL Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05596266
• Other study ID #: 202001
• Status: Recruiting
• Phase: Phase 1
• Start date: October 25, 2022
• Est. completion date: October 25, 2025

Study information

• Verified date: October 2022
• Source: Xuanwu Hospital, Beijing
• Contact: Zhiguo Chen, PhD
• Phone: 86-10-83198889
• Email: chenzhiguo[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I, interventional, single arm, open label, clinical study to evaluate the safety and tolerability of CD5 CAR-T cells in refractory/relapsed CD5+ T-ALL patients who have no available curative treatment options.

Description:

T-acute lymphoblast leukemia (T-ALL) is a neoplastic lymphoid leukemia characterized by the proliferation of immature precursor T cells. The combined chemotherapy has significantly improved the prognosis of T-acute lymphoblast leukemia/lymphoma. However, once the disease appears to be relapsed/refractory, there is limited treatment options, and the overall prognosis is extremely poor. Therefore, exploring safe and effective treatments is a critical unmet medical need. The patients will receive infusion of CAR T-cells targeting CD5 to examine the safety and, possibly the efficacy of CD5 CAR T-Cells in CD5+ relapsed or refractory acute leukemia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: October 25, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 18 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) according to the NCCN 2019.V2 Guideline. Refractory T-ALL is defined as a patient who has failed to achieve complete remission after induction therapy. Relapsed T-ALL is defined as the reappearance of blasts (5%) in either peripheral blood or bone marrow. Patients whose tumor burden >5% blasts, or who have persistent positive minimal residual disease (MRD), or have reappearance of extramedullary lesions are also considered eligible;

2. CD5-positive tumor (=70% CD5 positive blasts by flow cytometry or immunohistochemistry (tissue) assessed by a CLIA certified Flow Cytometry/Pathology laboratory). tumors burden >5%,or MRD+, or new extramedullary lesions reappeared;

3. Aged 1 to 18 years (including 18 years old);

4. Eastern Cooperative Oncology Group (ECOG) score 0-2;

5. Life expectancy greater than 12 weeks;

6. Oxygen saturation of blood>90%;

7. Total bilirubin (TBil) =3 × upper limit normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 10 × upper limit of normal;

8. Informed consent explained to, understood by and signed by patient/guardian.

Exclusion Criteria:

1. Intracranial hypertension or brain consciousness disorder;

2. Has an active GvHD;

3. Has a history of severe pulmonary function damaging;

4. With other tumors which is/are in advanced malignant stage and has/have systemic metastasis;

5. Severe or persistent infection that cannot be effectively controlled;

6. Presence of severe autoimmune diseases or immunodeficiency disease;

7. Patients with active hepatitis B or hepatitis C ([HBVDNA+] or [HCVRNA+]);

8. Patients with HIV infection or syphilis infection;

9. Has a history of serious allergies to biological products (including antibiotics);

10. Clinically significant viral infection or uncontrolled viral reactivation of EBV (Epstein-Barr virus), CMV (cytomegalovirus), ADV (adenovirus), BK-virus, or HHV (human herpesvirus)-6;

11. Presence of any symptomatic CNS disorder such as an uncontrolled seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement;

12. Received allogeneic hematopoietic stem cell transplantation within 6 months;

13. Being pregnant and lactating or having pregnancy within 12 months;

14. Any situations that the researchers believe will increase the risk for the subject or affect the results of the study.

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
• T-cell Acute Lymphoblastic Leukemia

Intervention

Biological:
• CD5 CAR-T
CD5 CAR-T will be administered by I.V. infusion.

Locations

Country	Name	City	State
China	Xuanwu Hospital Capital Medical University	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Xuanwu Hospital, Beijing	Baoding Children's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety: Incidence and severity of adverse events	To evaluate the possible adverse events occurred within the first one month following CD5 CAR-T infusion, including the incidence and severity of symptoms such as cytokine release syndrome and neurotoxicity.	First 1 month post CAR-T cells infusion
Secondary	Efficacy: Remission Rate	Remission Rate including complete remission(CR)?CR with incomplete blood count recovery(CRi)?partial remission(PR), No remission(NR), overall remission (OR).	1 months post CAR-T cells infusion
Secondary	Best overall response (BOR)	Best overall response (BOR) of complete remission (CR) or CR with incomplete blood count recovery (CRi) within 1 months after CD5 CAR-T infusion.	1 months
Secondary	Duration of remission (DoR)	Duration of remission (DoR) within 1 year following CD5 CAR-T infusion (DoR is defined as the duration from the date when the response criteria of CR or CRi is first met to the date of relapse or death due to ALL).	1 year
Secondary	Event free survival within 1 year	Event free survival (EFS) within 1 year (EFS is defined as the time from start of the first infusion to the earliest of death from any cause or relapse).	1 year